Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
13,253
archived clinical trials in
Arthritis

A Multi-center Study a Single IV Infusion of Allogeneic MPCs in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor
A Double-blind, Randomized, Placebo-controlled, Dose-escalation, Multi-center Study a Single Intravenous Infusion of Allogeneic Mesenchymal Precursor Cells (MPCs) in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor
Status: Enrolling
Updated:  4/5/2018
West Tennessee Research Institute
mi
from
Jackson, TN
A Multi-center Study a Single IV Infusion of Allogeneic MPCs in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor
A Double-blind, Randomized, Placebo-controlled, Dose-escalation, Multi-center Study a Single Intravenous Infusion of Allogeneic Mesenchymal Precursor Cells (MPCs) in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor
Status: Enrolling
Updated: 4/5/2018
West Tennessee Research Institute
mi
from
Jackson, TN
Click here to add this to my saved trials
A Multi-center Study a Single IV Infusion of Allogeneic MPCs in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor
A Double-blind, Randomized, Placebo-controlled, Dose-escalation, Multi-center Study a Single Intravenous Infusion of Allogeneic Mesenchymal Precursor Cells (MPCs) in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor
Status: Enrolling
Updated:  4/5/2018
Accurate Clinical Research
mi
from
Houston, TX
A Multi-center Study a Single IV Infusion of Allogeneic MPCs in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor
A Double-blind, Randomized, Placebo-controlled, Dose-escalation, Multi-center Study a Single Intravenous Infusion of Allogeneic Mesenchymal Precursor Cells (MPCs) in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor
Status: Enrolling
Updated: 4/5/2018
Accurate Clinical Research
mi
from
Houston, TX
Click here to add this to my saved trials
A Multi-center Study a Single IV Infusion of Allogeneic MPCs in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor
A Double-blind, Randomized, Placebo-controlled, Dose-escalation, Multi-center Study a Single Intravenous Infusion of Allogeneic Mesenchymal Precursor Cells (MPCs) in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor
Status: Enrolling
Updated:  4/5/2018
Pinnacle Research Group, LLC
mi
from
Anniston, AL
A Multi-center Study a Single IV Infusion of Allogeneic MPCs in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor
A Double-blind, Randomized, Placebo-controlled, Dose-escalation, Multi-center Study a Single Intravenous Infusion of Allogeneic Mesenchymal Precursor Cells (MPCs) in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor
Status: Enrolling
Updated: 4/5/2018
Pinnacle Research Group, LLC
mi
from
Anniston, AL
Click here to add this to my saved trials
A Multi-center Study a Single IV Infusion of Allogeneic MPCs in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor
A Double-blind, Randomized, Placebo-controlled, Dose-escalation, Multi-center Study a Single Intravenous Infusion of Allogeneic Mesenchymal Precursor Cells (MPCs) in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor
Status: Enrolling
Updated:  4/5/2018
TriWest Research Associates, LLC
mi
from
El Cajon, CA
A Multi-center Study a Single IV Infusion of Allogeneic MPCs in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor
A Double-blind, Randomized, Placebo-controlled, Dose-escalation, Multi-center Study a Single Intravenous Infusion of Allogeneic Mesenchymal Precursor Cells (MPCs) in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor
Status: Enrolling
Updated: 4/5/2018
TriWest Research Associates, LLC
mi
from
El Cajon, CA
Click here to add this to my saved trials
A Multi-center Study a Single IV Infusion of Allogeneic MPCs in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor
A Double-blind, Randomized, Placebo-controlled, Dose-escalation, Multi-center Study a Single Intravenous Infusion of Allogeneic Mesenchymal Precursor Cells (MPCs) in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor
Status: Enrolling
Updated:  4/5/2018
The Arthritis Center
mi
from
Palm Harbor, FL
A Multi-center Study a Single IV Infusion of Allogeneic MPCs in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor
A Double-blind, Randomized, Placebo-controlled, Dose-escalation, Multi-center Study a Single Intravenous Infusion of Allogeneic Mesenchymal Precursor Cells (MPCs) in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor
Status: Enrolling
Updated: 4/5/2018
The Arthritis Center
mi
from
Palm Harbor, FL
Click here to add this to my saved trials
A Multi-center Study a Single IV Infusion of Allogeneic MPCs in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor
A Double-blind, Randomized, Placebo-controlled, Dose-escalation, Multi-center Study a Single Intravenous Infusion of Allogeneic Mesenchymal Precursor Cells (MPCs) in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor
Status: Enrolling
Updated:  4/5/2018
Sarasota Arthritis Research Center
mi
from
Sarasota, FL
A Multi-center Study a Single IV Infusion of Allogeneic MPCs in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor
A Double-blind, Randomized, Placebo-controlled, Dose-escalation, Multi-center Study a Single Intravenous Infusion of Allogeneic Mesenchymal Precursor Cells (MPCs) in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor
Status: Enrolling
Updated: 4/5/2018
Sarasota Arthritis Research Center
mi
from
Sarasota, FL
Click here to add this to my saved trials
A Multi-center Study a Single IV Infusion of Allogeneic MPCs in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor
A Double-blind, Randomized, Placebo-controlled, Dose-escalation, Multi-center Study a Single Intravenous Infusion of Allogeneic Mesenchymal Precursor Cells (MPCs) in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor
Status: Enrolling
Updated:  4/5/2018
McIlwain Medical Group
mi
from
Tampa, FL
A Multi-center Study a Single IV Infusion of Allogeneic MPCs in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor
A Double-blind, Randomized, Placebo-controlled, Dose-escalation, Multi-center Study a Single Intravenous Infusion of Allogeneic Mesenchymal Precursor Cells (MPCs) in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor
Status: Enrolling
Updated: 4/5/2018
McIlwain Medical Group
mi
from
Tampa, FL
Click here to add this to my saved trials
A Multi-center Study a Single IV Infusion of Allogeneic MPCs in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor
A Double-blind, Randomized, Placebo-controlled, Dose-escalation, Multi-center Study a Single Intravenous Infusion of Allogeneic Mesenchymal Precursor Cells (MPCs) in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor
Status: Enrolling
Updated:  4/5/2018
Reliant Medical Group
mi
from
Worcester, MA
A Multi-center Study a Single IV Infusion of Allogeneic MPCs in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor
A Double-blind, Randomized, Placebo-controlled, Dose-escalation, Multi-center Study a Single Intravenous Infusion of Allogeneic Mesenchymal Precursor Cells (MPCs) in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor
Status: Enrolling
Updated: 4/5/2018
Reliant Medical Group
mi
from
Worcester, MA
Click here to add this to my saved trials
A Multi-center Study a Single IV Infusion of Allogeneic MPCs in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor
A Double-blind, Randomized, Placebo-controlled, Dose-escalation, Multi-center Study a Single Intravenous Infusion of Allogeneic Mesenchymal Precursor Cells (MPCs) in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor
Status: Enrolling
Updated:  4/5/2018
University of Pittsburgh
mi
from
Pittsburgh, PA
A Multi-center Study a Single IV Infusion of Allogeneic MPCs in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor
A Double-blind, Randomized, Placebo-controlled, Dose-escalation, Multi-center Study a Single Intravenous Infusion of Allogeneic Mesenchymal Precursor Cells (MPCs) in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor
Status: Enrolling
Updated: 4/5/2018
University of Pittsburgh
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
A Multi-center Study a Single IV Infusion of Allogeneic MPCs in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor
A Double-blind, Randomized, Placebo-controlled, Dose-escalation, Multi-center Study a Single Intravenous Infusion of Allogeneic Mesenchymal Precursor Cells (MPCs) in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor
Status: Enrolling
Updated:  4/5/2018
Texas Arthritis Research Center
mi
from
San Antonio, TX
A Multi-center Study a Single IV Infusion of Allogeneic MPCs in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor
A Double-blind, Randomized, Placebo-controlled, Dose-escalation, Multi-center Study a Single Intravenous Infusion of Allogeneic Mesenchymal Precursor Cells (MPCs) in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor
Status: Enrolling
Updated: 4/5/2018
Texas Arthritis Research Center
mi
from
San Antonio, TX
Click here to add this to my saved trials
A Multi-center Study a Single IV Infusion of Allogeneic MPCs in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor
A Double-blind, Randomized, Placebo-controlled, Dose-escalation, Multi-center Study a Single Intravenous Infusion of Allogeneic Mesenchymal Precursor Cells (MPCs) in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor
Status: Enrolling
Updated:  4/5/2018
Royal Prince Alfred Hospital
mi
from
Camperdown,
A Multi-center Study a Single IV Infusion of Allogeneic MPCs in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor
A Double-blind, Randomized, Placebo-controlled, Dose-escalation, Multi-center Study a Single Intravenous Infusion of Allogeneic Mesenchymal Precursor Cells (MPCs) in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor
Status: Enrolling
Updated: 4/5/2018
Royal Prince Alfred Hospital
mi
from
Camperdown,
Click here to add this to my saved trials
Study of Subtalar Arthrodesis Using AlloStem® Versus Autologous Bone Graft
Study of Subtalar Arthrodesis Using AlloStem® Versus Autologous Bone Graft
Status: Enrolling
Updated:  4/11/2018
Campbell Clinic
mi
from
Germantown, TN
Study of Subtalar Arthrodesis Using AlloStem® Versus Autologous Bone Graft
Study of Subtalar Arthrodesis Using AlloStem® Versus Autologous Bone Graft
Status: Enrolling
Updated: 4/11/2018
Campbell Clinic
mi
from
Germantown, TN
Click here to add this to my saved trials
Study of Subtalar Arthrodesis Using AlloStem® Versus Autologous Bone Graft
Study of Subtalar Arthrodesis Using AlloStem® Versus Autologous Bone Graft
Status: Enrolling
Updated:  4/11/2018
Institute for Foot and Ankle Reconstruction at Mercy
mi
from
Baltimore, MD
Study of Subtalar Arthrodesis Using AlloStem® Versus Autologous Bone Graft
Study of Subtalar Arthrodesis Using AlloStem® Versus Autologous Bone Graft
Status: Enrolling
Updated: 4/11/2018
Institute for Foot and Ankle Reconstruction at Mercy
mi
from
Baltimore, MD
Click here to add this to my saved trials
Study of Subtalar Arthrodesis Using AlloStem® Versus Autologous Bone Graft
Study of Subtalar Arthrodesis Using AlloStem® Versus Autologous Bone Graft
Status: Enrolling
Updated:  4/11/2018
Minnesota Orthopedic Sports Medicine Institute (MOSMI)
mi
from
Edina, MN
Study of Subtalar Arthrodesis Using AlloStem® Versus Autologous Bone Graft
Study of Subtalar Arthrodesis Using AlloStem® Versus Autologous Bone Graft
Status: Enrolling
Updated: 4/11/2018
Minnesota Orthopedic Sports Medicine Institute (MOSMI)
mi
from
Edina, MN
Click here to add this to my saved trials
Study of Subtalar Arthrodesis Using AlloStem® Versus Autologous Bone Graft
Study of Subtalar Arthrodesis Using AlloStem® Versus Autologous Bone Graft
Status: Enrolling
Updated:  4/11/2018
Orthopaedic Associates of Michigan
mi
from
Grand Rapids, MI
Study of Subtalar Arthrodesis Using AlloStem® Versus Autologous Bone Graft
Study of Subtalar Arthrodesis Using AlloStem® Versus Autologous Bone Graft
Status: Enrolling
Updated: 4/11/2018
Orthopaedic Associates of Michigan
mi
from
Grand Rapids, MI
Click here to add this to my saved trials
Study of Subtalar Arthrodesis Using AlloStem® Versus Autologous Bone Graft
Study of Subtalar Arthrodesis Using AlloStem® Versus Autologous Bone Graft
Status: Enrolling
Updated:  4/11/2018
Penn State Milton S. Hershey Medical Center
mi
from
Hershey, PA
Study of Subtalar Arthrodesis Using AlloStem® Versus Autologous Bone Graft
Study of Subtalar Arthrodesis Using AlloStem® Versus Autologous Bone Graft
Status: Enrolling
Updated: 4/11/2018
Penn State Milton S. Hershey Medical Center
mi
from
Hershey, PA
Click here to add this to my saved trials
BI 655066/ABBV-066/Risankizumab Compared to Placebo in Patients With Active Psoriatic Arthritis
A Randomised, Double-blind, Placebo-controlled, Proof-of-concept, Dose-ranging Study of BI 655066/ABBV-066/Risankizumabin Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  4/11/2018
1220.19.0007 Boehringer Ingelheim Investigational Site
mi
from
Palm Desert, CA
BI 655066/ABBV-066/Risankizumab Compared to Placebo in Patients With Active Psoriatic Arthritis
A Randomised, Double-blind, Placebo-controlled, Proof-of-concept, Dose-ranging Study of BI 655066/ABBV-066/Risankizumabin Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 4/11/2018
1220.19.0007 Boehringer Ingelheim Investigational Site
mi
from
Palm Desert, CA
Click here to add this to my saved trials
BI 655066/ABBV-066/Risankizumab Compared to Placebo in Patients With Active Psoriatic Arthritis
A Randomised, Double-blind, Placebo-controlled, Proof-of-concept, Dose-ranging Study of BI 655066/ABBV-066/Risankizumabin Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  4/11/2018
1301.1.5807 Boehringer Ingelheim Investigational Site
mi
from
Upland, CA
BI 655066/ABBV-066/Risankizumab Compared to Placebo in Patients With Active Psoriatic Arthritis
A Randomised, Double-blind, Placebo-controlled, Proof-of-concept, Dose-ranging Study of BI 655066/ABBV-066/Risankizumabin Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 4/11/2018
1301.1.5807 Boehringer Ingelheim Investigational Site
mi
from
Upland, CA
Click here to add this to my saved trials
BI 655066/ABBV-066/Risankizumab Compared to Placebo in Patients With Active Psoriatic Arthritis
A Randomised, Double-blind, Placebo-controlled, Proof-of-concept, Dose-ranging Study of BI 655066/ABBV-066/Risankizumabin Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  4/11/2018
1199.15.10027 Boehringer Ingelheim Investigational Site
mi
from
Tampa, FL
BI 655066/ABBV-066/Risankizumab Compared to Placebo in Patients With Active Psoriatic Arthritis
A Randomised, Double-blind, Placebo-controlled, Proof-of-concept, Dose-ranging Study of BI 655066/ABBV-066/Risankizumabin Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 4/11/2018
1199.15.10027 Boehringer Ingelheim Investigational Site
mi
from
Tampa, FL
Click here to add this to my saved trials
BI 655066/ABBV-066/Risankizumab Compared to Placebo in Patients With Active Psoriatic Arthritis
A Randomised, Double-blind, Placebo-controlled, Proof-of-concept, Dose-ranging Study of BI 655066/ABBV-066/Risankizumabin Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  4/11/2018
1245.23.10148 Boehringer Ingelheim Investigational Site
mi
from
Lexington, KY
BI 655066/ABBV-066/Risankizumab Compared to Placebo in Patients With Active Psoriatic Arthritis
A Randomised, Double-blind, Placebo-controlled, Proof-of-concept, Dose-ranging Study of BI 655066/ABBV-066/Risankizumabin Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 4/11/2018
1245.23.10148 Boehringer Ingelheim Investigational Site
mi
from
Lexington, KY
Click here to add this to my saved trials
BI 655066/ABBV-066/Risankizumab Compared to Placebo in Patients With Active Psoriatic Arthritis
A Randomised, Double-blind, Placebo-controlled, Proof-of-concept, Dose-ranging Study of BI 655066/ABBV-066/Risankizumabin Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  4/11/2018
1200.45.066 Boehringer Ingelheim Investigational Site
mi
from
Freehold, NJ
BI 655066/ABBV-066/Risankizumab Compared to Placebo in Patients With Active Psoriatic Arthritis
A Randomised, Double-blind, Placebo-controlled, Proof-of-concept, Dose-ranging Study of BI 655066/ABBV-066/Risankizumabin Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 4/11/2018
1200.45.066 Boehringer Ingelheim Investigational Site
mi
from
Freehold, NJ
Click here to add this to my saved trials
BI 655066/ABBV-066/Risankizumab Compared to Placebo in Patients With Active Psoriatic Arthritis
A Randomised, Double-blind, Placebo-controlled, Proof-of-concept, Dose-ranging Study of BI 655066/ABBV-066/Risankizumabin Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  4/11/2018
1301.1.5557 Boehringer Ingelheim Investigational Site
mi
from
Duncansville, PA
BI 655066/ABBV-066/Risankizumab Compared to Placebo in Patients With Active Psoriatic Arthritis
A Randomised, Double-blind, Placebo-controlled, Proof-of-concept, Dose-ranging Study of BI 655066/ABBV-066/Risankizumabin Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 4/11/2018
1301.1.5557 Boehringer Ingelheim Investigational Site
mi
from
Duncansville, PA
Click here to add this to my saved trials
BI 655066/ABBV-066/Risankizumab Compared to Placebo in Patients With Active Psoriatic Arthritis
A Randomised, Double-blind, Placebo-controlled, Proof-of-concept, Dose-ranging Study of BI 655066/ABBV-066/Risankizumabin Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  4/11/2018
Boehringer Ingelheim Investigational Site
mi
from
Charleston, SC
BI 655066/ABBV-066/Risankizumab Compared to Placebo in Patients With Active Psoriatic Arthritis
A Randomised, Double-blind, Placebo-controlled, Proof-of-concept, Dose-ranging Study of BI 655066/ABBV-066/Risankizumabin Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 4/11/2018
Boehringer Ingelheim Investigational Site
mi
from
Charleston, SC
Click here to add this to my saved trials
BI 655066/ABBV-066/Risankizumab Compared to Placebo in Patients With Active Psoriatic Arthritis
A Randomised, Double-blind, Placebo-controlled, Proof-of-concept, Dose-ranging Study of BI 655066/ABBV-066/Risankizumabin Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  4/11/2018
1160.129.32338 Boehringer Ingelheim Investigational Site
mi
from
Jackson, TN
BI 655066/ABBV-066/Risankizumab Compared to Placebo in Patients With Active Psoriatic Arthritis
A Randomised, Double-blind, Placebo-controlled, Proof-of-concept, Dose-ranging Study of BI 655066/ABBV-066/Risankizumabin Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 4/11/2018
1160.129.32338 Boehringer Ingelheim Investigational Site
mi
from
Jackson, TN
Click here to add this to my saved trials
BI 655066/ABBV-066/Risankizumab Compared to Placebo in Patients With Active Psoriatic Arthritis
A Randomised, Double-blind, Placebo-controlled, Proof-of-concept, Dose-ranging Study of BI 655066/ABBV-066/Risankizumabin Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  4/11/2018
1270.1.32001 Boehringer Ingelheim Investigational Site
mi
from
Bruxelles,
BI 655066/ABBV-066/Risankizumab Compared to Placebo in Patients With Active Psoriatic Arthritis
A Randomised, Double-blind, Placebo-controlled, Proof-of-concept, Dose-ranging Study of BI 655066/ABBV-066/Risankizumabin Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 4/11/2018
1270.1.32001 Boehringer Ingelheim Investigational Site
mi
from
Bruxelles,
Click here to add this to my saved trials
BI 655066/ABBV-066/Risankizumab Compared to Placebo in Patients With Active Psoriatic Arthritis
A Randomised, Double-blind, Placebo-controlled, Proof-of-concept, Dose-ranging Study of BI 655066/ABBV-066/Risankizumabin Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  4/11/2018
1199.14.1158 Boehringer Ingelheim Investigational Site
mi
from
Seattle, WA
BI 655066/ABBV-066/Risankizumab Compared to Placebo in Patients With Active Psoriatic Arthritis
A Randomised, Double-blind, Placebo-controlled, Proof-of-concept, Dose-ranging Study of BI 655066/ABBV-066/Risankizumabin Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 4/11/2018
1199.14.1158 Boehringer Ingelheim Investigational Site
mi
from
Seattle, WA
Click here to add this to my saved trials
Pro-calcitonin for Early Detection of Septic Arthritis
Pro-calcitonin for Early Detection of Septic Arthritis
Status: Enrolling
Updated:  4/18/2018
Children's Hospitals and Clinics of Minnesota
mi
from
Minneapolis, MN
Pro-calcitonin for Early Detection of Septic Arthritis
Pro-calcitonin for Early Detection of Septic Arthritis
Status: Enrolling
Updated: 4/18/2018
Children's Hospitals and Clinics of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Evaluation of Methods of Teaching Self-management Strategies to Patients With Symptomatic Knee Osteoarthritis
Evaluation of Different Methods of Teaching Self-management Strategies to Patients With Symptomatic Knee Osteoarthritis
Status: Enrolling
Updated:  4/19/2018
Hospital for Special Surgery
mi
from
New York, NY
Evaluation of Methods of Teaching Self-management Strategies to Patients With Symptomatic Knee Osteoarthritis
Evaluation of Different Methods of Teaching Self-management Strategies to Patients With Symptomatic Knee Osteoarthritis
Status: Enrolling
Updated: 4/19/2018
Hospital for Special Surgery
mi
from
New York, NY
Click here to add this to my saved trials
Phase IIB Dose Ranging Study in Subjects With Moderate to Severe Rheumatoid Arthritis
A Phase IIb, Randomized, Multi-Center, Double-Blind, Dose-Ranging Study to Evaluate the Efficacy and Safety of Clazakizumab in Subjects With Moderate to Severe Active Rheumatoid Arthritis Who Have Experienced an Inadequate Response to TNF Inhibitors
Status: Enrolling
Updated:  4/20/2018
Rheumatology Associates Of North Alabama, P.C.
mi
from
Huntsville, AL
Phase IIB Dose Ranging Study in Subjects With Moderate to Severe Rheumatoid Arthritis
A Phase IIb, Randomized, Multi-Center, Double-Blind, Dose-Ranging Study to Evaluate the Efficacy and Safety of Clazakizumab in Subjects With Moderate to Severe Active Rheumatoid Arthritis Who Have Experienced an Inadequate Response to TNF Inhibitors
Status: Enrolling
Updated: 4/20/2018
Rheumatology Associates Of North Alabama, P.C.
mi
from
Huntsville, AL
Click here to add this to my saved trials
Phase IIB Dose Ranging Study in Subjects With Moderate to Severe Rheumatoid Arthritis
A Phase IIb, Randomized, Multi-Center, Double-Blind, Dose-Ranging Study to Evaluate the Efficacy and Safety of Clazakizumab in Subjects With Moderate to Severe Active Rheumatoid Arthritis Who Have Experienced an Inadequate Response to TNF Inhibitors
Status: Enrolling
Updated:  4/20/2018
Mercy Clinic Hot Springs Communities
mi
from
Hot Springs, AR
Phase IIB Dose Ranging Study in Subjects With Moderate to Severe Rheumatoid Arthritis
A Phase IIb, Randomized, Multi-Center, Double-Blind, Dose-Ranging Study to Evaluate the Efficacy and Safety of Clazakizumab in Subjects With Moderate to Severe Active Rheumatoid Arthritis Who Have Experienced an Inadequate Response to TNF Inhibitors
Status: Enrolling
Updated: 4/20/2018
Mercy Clinic Hot Springs Communities
mi
from
Hot Springs, AR
Click here to add this to my saved trials
Phase IIB Dose Ranging Study in Subjects With Moderate to Severe Rheumatoid Arthritis
A Phase IIb, Randomized, Multi-Center, Double-Blind, Dose-Ranging Study to Evaluate the Efficacy and Safety of Clazakizumab in Subjects With Moderate to Severe Active Rheumatoid Arthritis Who Have Experienced an Inadequate Response to TNF Inhibitors
Status: Enrolling
Updated:  4/20/2018
Valerius Med Group & Res Ctr Of Greater Long Beach, Inc.
mi
from
Long Beach, CA
Phase IIB Dose Ranging Study in Subjects With Moderate to Severe Rheumatoid Arthritis
A Phase IIb, Randomized, Multi-Center, Double-Blind, Dose-Ranging Study to Evaluate the Efficacy and Safety of Clazakizumab in Subjects With Moderate to Severe Active Rheumatoid Arthritis Who Have Experienced an Inadequate Response to TNF Inhibitors
Status: Enrolling
Updated: 4/20/2018
Valerius Med Group & Res Ctr Of Greater Long Beach, Inc.
mi
from
Long Beach, CA
Click here to add this to my saved trials
Phase IIB Dose Ranging Study in Subjects With Moderate to Severe Rheumatoid Arthritis
A Phase IIb, Randomized, Multi-Center, Double-Blind, Dose-Ranging Study to Evaluate the Efficacy and Safety of Clazakizumab in Subjects With Moderate to Severe Active Rheumatoid Arthritis Who Have Experienced an Inadequate Response to TNF Inhibitors
Status: Enrolling
Updated:  4/20/2018
Desert Medical Advances
mi
from
Palm Desert, CA
Phase IIB Dose Ranging Study in Subjects With Moderate to Severe Rheumatoid Arthritis
A Phase IIb, Randomized, Multi-Center, Double-Blind, Dose-Ranging Study to Evaluate the Efficacy and Safety of Clazakizumab in Subjects With Moderate to Severe Active Rheumatoid Arthritis Who Have Experienced an Inadequate Response to TNF Inhibitors
Status: Enrolling
Updated: 4/20/2018
Desert Medical Advances
mi
from
Palm Desert, CA
Click here to add this to my saved trials
Phase IIB Dose Ranging Study in Subjects With Moderate to Severe Rheumatoid Arthritis
A Phase IIb, Randomized, Multi-Center, Double-Blind, Dose-Ranging Study to Evaluate the Efficacy and Safety of Clazakizumab in Subjects With Moderate to Severe Active Rheumatoid Arthritis Who Have Experienced an Inadequate Response to TNF Inhibitors
Status: Enrolling
Updated:  4/20/2018
Sarasota Arthritis Research Center
mi
from
Sarasota, FL
Phase IIB Dose Ranging Study in Subjects With Moderate to Severe Rheumatoid Arthritis
A Phase IIb, Randomized, Multi-Center, Double-Blind, Dose-Ranging Study to Evaluate the Efficacy and Safety of Clazakizumab in Subjects With Moderate to Severe Active Rheumatoid Arthritis Who Have Experienced an Inadequate Response to TNF Inhibitors
Status: Enrolling
Updated: 4/20/2018
Sarasota Arthritis Research Center
mi
from
Sarasota, FL
Click here to add this to my saved trials
Phase IIB Dose Ranging Study in Subjects With Moderate to Severe Rheumatoid Arthritis
A Phase IIb, Randomized, Multi-Center, Double-Blind, Dose-Ranging Study to Evaluate the Efficacy and Safety of Clazakizumab in Subjects With Moderate to Severe Active Rheumatoid Arthritis Who Have Experienced an Inadequate Response to TNF Inhibitors
Status: Enrolling
Updated:  4/20/2018
Clinical Pharmacology Study Group
mi
from
Worcester, MA
Phase IIB Dose Ranging Study in Subjects With Moderate to Severe Rheumatoid Arthritis
A Phase IIb, Randomized, Multi-Center, Double-Blind, Dose-Ranging Study to Evaluate the Efficacy and Safety of Clazakizumab in Subjects With Moderate to Severe Active Rheumatoid Arthritis Who Have Experienced an Inadequate Response to TNF Inhibitors
Status: Enrolling
Updated: 4/20/2018
Clinical Pharmacology Study Group
mi
from
Worcester, MA
Click here to add this to my saved trials
Phase IIB Dose Ranging Study in Subjects With Moderate to Severe Rheumatoid Arthritis
A Phase IIb, Randomized, Multi-Center, Double-Blind, Dose-Ranging Study to Evaluate the Efficacy and Safety of Clazakizumab in Subjects With Moderate to Severe Active Rheumatoid Arthritis Who Have Experienced an Inadequate Response to TNF Inhibitors
Status: Enrolling
Updated:  4/20/2018
St. Paul Rheumatology, PA
mi
from
Eagan, MN
Phase IIB Dose Ranging Study in Subjects With Moderate to Severe Rheumatoid Arthritis
A Phase IIb, Randomized, Multi-Center, Double-Blind, Dose-Ranging Study to Evaluate the Efficacy and Safety of Clazakizumab in Subjects With Moderate to Severe Active Rheumatoid Arthritis Who Have Experienced an Inadequate Response to TNF Inhibitors
Status: Enrolling
Updated: 4/20/2018
St. Paul Rheumatology, PA
mi
from
Eagan, MN
Click here to add this to my saved trials
Phase IIB Dose Ranging Study in Subjects With Moderate to Severe Rheumatoid Arthritis
A Phase IIb, Randomized, Multi-Center, Double-Blind, Dose-Ranging Study to Evaluate the Efficacy and Safety of Clazakizumab in Subjects With Moderate to Severe Active Rheumatoid Arthritis Who Have Experienced an Inadequate Response to TNF Inhibitors
Status: Enrolling
Updated:  4/20/2018
Physician Research Collaboration
mi
from
Lincoln, NE
Phase IIB Dose Ranging Study in Subjects With Moderate to Severe Rheumatoid Arthritis
A Phase IIb, Randomized, Multi-Center, Double-Blind, Dose-Ranging Study to Evaluate the Efficacy and Safety of Clazakizumab in Subjects With Moderate to Severe Active Rheumatoid Arthritis Who Have Experienced an Inadequate Response to TNF Inhibitors
Status: Enrolling
Updated: 4/20/2018
Physician Research Collaboration
mi
from
Lincoln, NE
Click here to add this to my saved trials
Phase IIB Dose Ranging Study in Subjects With Moderate to Severe Rheumatoid Arthritis
A Phase IIb, Randomized, Multi-Center, Double-Blind, Dose-Ranging Study to Evaluate the Efficacy and Safety of Clazakizumab in Subjects With Moderate to Severe Active Rheumatoid Arthritis Who Have Experienced an Inadequate Response to TNF Inhibitors
Status: Enrolling
Updated:  4/20/2018
Albuquerque Center For Rheumatology
mi
from
Albuquerque, NM
Phase IIB Dose Ranging Study in Subjects With Moderate to Severe Rheumatoid Arthritis
A Phase IIb, Randomized, Multi-Center, Double-Blind, Dose-Ranging Study to Evaluate the Efficacy and Safety of Clazakizumab in Subjects With Moderate to Severe Active Rheumatoid Arthritis Who Have Experienced an Inadequate Response to TNF Inhibitors
Status: Enrolling
Updated: 4/20/2018
Albuquerque Center For Rheumatology
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Phase IIB Dose Ranging Study in Subjects With Moderate to Severe Rheumatoid Arthritis
A Phase IIb, Randomized, Multi-Center, Double-Blind, Dose-Ranging Study to Evaluate the Efficacy and Safety of Clazakizumab in Subjects With Moderate to Severe Active Rheumatoid Arthritis Who Have Experienced an Inadequate Response to TNF Inhibitors
Status: Enrolling
Updated:  4/20/2018
Albuquerque Clinical Trials
mi
from
Albuquerque, NM
Phase IIB Dose Ranging Study in Subjects With Moderate to Severe Rheumatoid Arthritis
A Phase IIb, Randomized, Multi-Center, Double-Blind, Dose-Ranging Study to Evaluate the Efficacy and Safety of Clazakizumab in Subjects With Moderate to Severe Active Rheumatoid Arthritis Who Have Experienced an Inadequate Response to TNF Inhibitors
Status: Enrolling
Updated: 4/20/2018
Albuquerque Clinical Trials
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Phase IIB Dose Ranging Study in Subjects With Moderate to Severe Rheumatoid Arthritis
A Phase IIb, Randomized, Multi-Center, Double-Blind, Dose-Ranging Study to Evaluate the Efficacy and Safety of Clazakizumab in Subjects With Moderate to Severe Active Rheumatoid Arthritis Who Have Experienced an Inadequate Response to TNF Inhibitors
Status: Enrolling
Updated:  4/20/2018
Joint And Muscle Medical Care And Research Institute (Jmmcri)
mi
from
Charlotte, NC
Phase IIB Dose Ranging Study in Subjects With Moderate to Severe Rheumatoid Arthritis
A Phase IIb, Randomized, Multi-Center, Double-Blind, Dose-Ranging Study to Evaluate the Efficacy and Safety of Clazakizumab in Subjects With Moderate to Severe Active Rheumatoid Arthritis Who Have Experienced an Inadequate Response to TNF Inhibitors
Status: Enrolling
Updated: 4/20/2018
Joint And Muscle Medical Care And Research Institute (Jmmcri)
mi
from
Charlotte, NC
Click here to add this to my saved trials
Phase IIB Dose Ranging Study in Subjects With Moderate to Severe Rheumatoid Arthritis
A Phase IIb, Randomized, Multi-Center, Double-Blind, Dose-Ranging Study to Evaluate the Efficacy and Safety of Clazakizumab in Subjects With Moderate to Severe Active Rheumatoid Arthritis Who Have Experienced an Inadequate Response to TNF Inhibitors
Status: Enrolling
Updated:  4/20/2018
Physician's East
mi
from
Greenville, NC
Phase IIB Dose Ranging Study in Subjects With Moderate to Severe Rheumatoid Arthritis
A Phase IIb, Randomized, Multi-Center, Double-Blind, Dose-Ranging Study to Evaluate the Efficacy and Safety of Clazakizumab in Subjects With Moderate to Severe Active Rheumatoid Arthritis Who Have Experienced an Inadequate Response to TNF Inhibitors
Status: Enrolling
Updated: 4/20/2018
Physician's East
mi
from
Greenville, NC
Click here to add this to my saved trials
Phase IIB Dose Ranging Study in Subjects With Moderate to Severe Rheumatoid Arthritis
A Phase IIb, Randomized, Multi-Center, Double-Blind, Dose-Ranging Study to Evaluate the Efficacy and Safety of Clazakizumab in Subjects With Moderate to Severe Active Rheumatoid Arthritis Who Have Experienced an Inadequate Response to TNF Inhibitors
Status: Enrolling
Updated:  4/20/2018
Cincinnati Rheumatic Disease Study Group
mi
from
Cincinnati, OH
Phase IIB Dose Ranging Study in Subjects With Moderate to Severe Rheumatoid Arthritis
A Phase IIb, Randomized, Multi-Center, Double-Blind, Dose-Ranging Study to Evaluate the Efficacy and Safety of Clazakizumab in Subjects With Moderate to Severe Active Rheumatoid Arthritis Who Have Experienced an Inadequate Response to TNF Inhibitors
Status: Enrolling
Updated: 4/20/2018
Cincinnati Rheumatic Disease Study Group
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Phase IIB Dose Ranging Study in Subjects With Moderate to Severe Rheumatoid Arthritis
A Phase IIb, Randomized, Multi-Center, Double-Blind, Dose-Ranging Study to Evaluate the Efficacy and Safety of Clazakizumab in Subjects With Moderate to Severe Active Rheumatoid Arthritis Who Have Experienced an Inadequate Response to TNF Inhibitors
Status: Enrolling
Updated:  4/20/2018
Paramount Medical Research & Consulting, Llc
mi
from
Middleburg Heights, OH
Phase IIB Dose Ranging Study in Subjects With Moderate to Severe Rheumatoid Arthritis
A Phase IIb, Randomized, Multi-Center, Double-Blind, Dose-Ranging Study to Evaluate the Efficacy and Safety of Clazakizumab in Subjects With Moderate to Severe Active Rheumatoid Arthritis Who Have Experienced an Inadequate Response to TNF Inhibitors
Status: Enrolling
Updated: 4/20/2018
Paramount Medical Research & Consulting, Llc
mi
from
Middleburg Heights, OH
Click here to add this to my saved trials
Phase IIB Dose Ranging Study in Subjects With Moderate to Severe Rheumatoid Arthritis
A Phase IIb, Randomized, Multi-Center, Double-Blind, Dose-Ranging Study to Evaluate the Efficacy and Safety of Clazakizumab in Subjects With Moderate to Severe Active Rheumatoid Arthritis Who Have Experienced an Inadequate Response to TNF Inhibitors
Status: Enrolling
Updated:  4/20/2018
Arthritis & Rheumatology Center Of Oklahoma Pllc
mi
from
Oklahoma City, OK
Phase IIB Dose Ranging Study in Subjects With Moderate to Severe Rheumatoid Arthritis
A Phase IIb, Randomized, Multi-Center, Double-Blind, Dose-Ranging Study to Evaluate the Efficacy and Safety of Clazakizumab in Subjects With Moderate to Severe Active Rheumatoid Arthritis Who Have Experienced an Inadequate Response to TNF Inhibitors
Status: Enrolling
Updated: 4/20/2018
Arthritis & Rheumatology Center Of Oklahoma Pllc
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Phase IIB Dose Ranging Study in Subjects With Moderate to Severe Rheumatoid Arthritis
A Phase IIb, Randomized, Multi-Center, Double-Blind, Dose-Ranging Study to Evaluate the Efficacy and Safety of Clazakizumab in Subjects With Moderate to Severe Active Rheumatoid Arthritis Who Have Experienced an Inadequate Response to TNF Inhibitors
Status: Enrolling
Updated:  4/20/2018
Health Research of Oklahoma
mi
from
Oklahoma City, OK
Phase IIB Dose Ranging Study in Subjects With Moderate to Severe Rheumatoid Arthritis
A Phase IIb, Randomized, Multi-Center, Double-Blind, Dose-Ranging Study to Evaluate the Efficacy and Safety of Clazakizumab in Subjects With Moderate to Severe Active Rheumatoid Arthritis Who Have Experienced an Inadequate Response to TNF Inhibitors
Status: Enrolling
Updated: 4/20/2018
Health Research of Oklahoma
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Phase IIB Dose Ranging Study in Subjects With Moderate to Severe Rheumatoid Arthritis
A Phase IIb, Randomized, Multi-Center, Double-Blind, Dose-Ranging Study to Evaluate the Efficacy and Safety of Clazakizumab in Subjects With Moderate to Severe Active Rheumatoid Arthritis Who Have Experienced an Inadequate Response to TNF Inhibitors
Status: Enrolling
Updated:  4/20/2018
Healthcare Research Consultants
mi
from
Tulsa, OK
Phase IIB Dose Ranging Study in Subjects With Moderate to Severe Rheumatoid Arthritis
A Phase IIb, Randomized, Multi-Center, Double-Blind, Dose-Ranging Study to Evaluate the Efficacy and Safety of Clazakizumab in Subjects With Moderate to Severe Active Rheumatoid Arthritis Who Have Experienced an Inadequate Response to TNF Inhibitors
Status: Enrolling
Updated: 4/20/2018
Healthcare Research Consultants
mi
from
Tulsa, OK
Click here to add this to my saved trials
Phase IIB Dose Ranging Study in Subjects With Moderate to Severe Rheumatoid Arthritis
A Phase IIb, Randomized, Multi-Center, Double-Blind, Dose-Ranging Study to Evaluate the Efficacy and Safety of Clazakizumab in Subjects With Moderate to Severe Active Rheumatoid Arthritis Who Have Experienced an Inadequate Response to TNF Inhibitors
Status: Enrolling
Updated:  4/20/2018
Low Country Rheumatology
mi
from
Charleston, SC
Phase IIB Dose Ranging Study in Subjects With Moderate to Severe Rheumatoid Arthritis
A Phase IIb, Randomized, Multi-Center, Double-Blind, Dose-Ranging Study to Evaluate the Efficacy and Safety of Clazakizumab in Subjects With Moderate to Severe Active Rheumatoid Arthritis Who Have Experienced an Inadequate Response to TNF Inhibitors
Status: Enrolling
Updated: 4/20/2018
Low Country Rheumatology
mi
from
Charleston, SC
Click here to add this to my saved trials
Phase IIB Dose Ranging Study in Subjects With Moderate to Severe Rheumatoid Arthritis
A Phase IIb, Randomized, Multi-Center, Double-Blind, Dose-Ranging Study to Evaluate the Efficacy and Safety of Clazakizumab in Subjects With Moderate to Severe Active Rheumatoid Arthritis Who Have Experienced an Inadequate Response to TNF Inhibitors
Status: Enrolling
Updated:  4/20/2018
Rheumatology Consultants Pllc
mi
from
Knoxville, TN
Phase IIB Dose Ranging Study in Subjects With Moderate to Severe Rheumatoid Arthritis
A Phase IIb, Randomized, Multi-Center, Double-Blind, Dose-Ranging Study to Evaluate the Efficacy and Safety of Clazakizumab in Subjects With Moderate to Severe Active Rheumatoid Arthritis Who Have Experienced an Inadequate Response to TNF Inhibitors
Status: Enrolling
Updated: 4/20/2018
Rheumatology Consultants Pllc
mi
from
Knoxville, TN
Click here to add this to my saved trials
Phase IIB Dose Ranging Study in Subjects With Moderate to Severe Rheumatoid Arthritis
A Phase IIb, Randomized, Multi-Center, Double-Blind, Dose-Ranging Study to Evaluate the Efficacy and Safety of Clazakizumab in Subjects With Moderate to Severe Active Rheumatoid Arthritis Who Have Experienced an Inadequate Response to TNF Inhibitors
Status: Enrolling
Updated:  4/20/2018
Center For Inflammatory Disease
mi
from
Nashville, TN
Phase IIB Dose Ranging Study in Subjects With Moderate to Severe Rheumatoid Arthritis
A Phase IIb, Randomized, Multi-Center, Double-Blind, Dose-Ranging Study to Evaluate the Efficacy and Safety of Clazakizumab in Subjects With Moderate to Severe Active Rheumatoid Arthritis Who Have Experienced an Inadequate Response to TNF Inhibitors
Status: Enrolling
Updated: 4/20/2018
Center For Inflammatory Disease
mi
from
Nashville, TN
Click here to add this to my saved trials
Phase IIB Dose Ranging Study in Subjects With Moderate to Severe Rheumatoid Arthritis
A Phase IIb, Randomized, Multi-Center, Double-Blind, Dose-Ranging Study to Evaluate the Efficacy and Safety of Clazakizumab in Subjects With Moderate to Severe Active Rheumatoid Arthritis Who Have Experienced an Inadequate Response to TNF Inhibitors
Status: Enrolling
Updated:  4/20/2018
Seattle Rheumatology Associates
mi
from
Seattle, WA
Phase IIB Dose Ranging Study in Subjects With Moderate to Severe Rheumatoid Arthritis
A Phase IIb, Randomized, Multi-Center, Double-Blind, Dose-Ranging Study to Evaluate the Efficacy and Safety of Clazakizumab in Subjects With Moderate to Severe Active Rheumatoid Arthritis Who Have Experienced an Inadequate Response to TNF Inhibitors
Status: Enrolling
Updated: 4/20/2018
Seattle Rheumatology Associates
mi
from
Seattle, WA
Click here to add this to my saved trials
Phase IIB Dose Ranging Study in Subjects With Moderate to Severe Rheumatoid Arthritis
A Phase IIb, Randomized, Multi-Center, Double-Blind, Dose-Ranging Study to Evaluate the Efficacy and Safety of Clazakizumab in Subjects With Moderate to Severe Active Rheumatoid Arthritis Who Have Experienced an Inadequate Response to TNF Inhibitors
Status: Enrolling
Updated:  4/20/2018
Local Institution
mi
from
Quilmes,
Phase IIB Dose Ranging Study in Subjects With Moderate to Severe Rheumatoid Arthritis
A Phase IIb, Randomized, Multi-Center, Double-Blind, Dose-Ranging Study to Evaluate the Efficacy and Safety of Clazakizumab in Subjects With Moderate to Severe Active Rheumatoid Arthritis Who Have Experienced an Inadequate Response to TNF Inhibitors
Status: Enrolling
Updated: 4/20/2018
Local Institution
mi
from
Quilmes,
Click here to add this to my saved trials